Skip to main content
. 2024 Oct 23;18(44):30211–30223. doi: 10.1021/acsnano.4c09830

Figure 7.

Figure 7

Enzymatic degradation of uric acid using cell membrane-coated uricase-loaded MOF nanoparticles. (A) Schematic representation of the synthesis of cell membrane-coated uricase-loaded MOF nanoparticles for enzymatic uric acid degradation. The process begins with forming MOF-uricase cores by incorporating the enzyme into a framework composed of Zn(II) and 2-methylimidazole (mim). These cores are then encapsulated within cell membranes derived from RBCs or MΦs. (B) In vivo management of hyperuricemia. Serum uric acid levels over time in hyperuricemic mice treated intravenously with either PBS, free uricase, or RBC-MOF-uricase. *p < 0.05, **p < 0.01 for PBS compared with RBC-MOF-uricase; &p < 0.05, &&p < 0.01 for free uricase compared with RBC-MOF-uricase. (C) In vivo management of gout. Changes in ankle joint diameter in gout-afflicted mice following intra-articular treatment with PBS, free uricase, MΦ-MOF, RBC-MOF-uricase, or MΦ-MOF-uricase. **p < 0.01, ****p < 0.0001 compared with MΦ-MOF-uricase at 48 h. Adapted with permission from ref (43). Copyright 2021, American Chemical Society.